Mabtech Establishes Strategic US.S. Collaboration - Mar 18

The Story

Mabtech announced on March 18, 2026 via PR Newswire that it has established a strategic U.S. collaboration with Sai Life Sciences to expand access to the EYRA™ Multiplex Immunology Platform. Sai Life Sciences' Boston site has been designated as a co-marketed U.S. execution hub for the EYRA platform, bringing high-sensitivity multiplex immune profiling to biopharma and biotech clients across the United States.

Why It Matters For Your Portfolio

• March 18, 2026 announcement, signaling immediate commercial intent in the U.S., which could increase market reach for the EYRA platform.
• Sai's Boston site is named as the co-marketed U.S. execution hub, potentially improving onshore access for biopharma and biotech clients that need high-sensitivity multiplex immune profiling.
• The release discloses no pricing, revenue, client counts, or expected financial impact, so near-term revenue implications remain unclear.
• This partnership could matter for investors tracking companies exposed to assay platforms, contract research execution, or immunology services, as it may accelerate commercial adoption of multiplex profiling tools.

The Trade

Growth and biotech-focused investors should watch for follow-up commercial details, announced client engagements, and any disclosed pricing or revenue figures that clarify financial impact. Traders may watch news flow around commercial rollout milestones and partnership updates to gauge momentum. This article is informational only and not personalized investment advice.